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The dysregulation of microRNAs (miRNAs) is crucially implicated in the development of various
cancers. In this study, we explored the biological role of miR-141 in non-small cell lung cancer
(NSCLC). miR-141 expression was signiﬁcantly up-regulated in NSCLC tissues, and its overexpression
accelerated NSCLC cell proliferation in vitro and tumor growth in vivo. We subsequently identiﬁed
the antagonists of PI3K/AKT signaling, PH domain leucine-rich-repeats protein phosphatase 1
(PHLPP1) and PHLPP2, as direct targets of miR-141. Re-introduction of PHLPP1 and PHLPP2
abrogated miR-141-induced proliferation of NSCLC cells. Together, the results of this study suggest
that miR-141 and its targets PHLPP1 and PHLPP2 play critical roles in NSCLC tumorigenesis, and
provide potential therapeutic targets for NSCLC treatment.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Non-small cell lung cancer (NSCLC), including adenocarcinoma
(ADC), squamous cell carcinoma (SCC), adenosquamous cell carci-
noma and large cell carcinoma (LCC), accounts for 80–85% of all
lung cancer cases [1,2]. The overall 5-year survival rate for NSCLC
patients has remained unchanged at approximately 15%, despite
recent advances in surgical therapy, radiotherapy and chemother-
apy [2]. An improved understanding of the molecular mechanisms
regulating its development and progression is therefore needed to
help to generate more effective therapies. Non-coding small RNAs
have been proven to play an role in NSCLC pathogenesis [3,4],
providing novel insights into potential new diagnostic and
therapeutic approaches to this disease.
MicroRNAs (miRNAs) are evolutionarily conserved, endogenous
non-coding RNAs of about 22 nucleotides that post-transcription-
ally regulate gene expression through binding to the 30-untrans-
lated region (30-UTR) of target mRNAs in a sequence-speciﬁc
manner [5]. They play crucial roles in various biological processes
such as proliferation, development, differentiation, invasion,apoptosis and metabolism [6]. Moreover, increasing evidence has
implicated dysregulation of miRNAs in the pathogenesis and devel-
opment of various human cancers [7,8]. Several miRNAs, such as
miR-205 and miR-195, have been shown to be dysregulated in
NSCLC and contribute to the development and progression of NSCLC
[3,4]. Human miRNA-141 (miR-141), a member of the miR-200
family, has been reportedly associated with various human malig-
nancies. miR-141 is up-regulated in ovarian cancer [9], but down-
regulated in hepatocellular and prostate cancers [10,11], indicating
different regulatory effects of miR-141 in various cancers.
In the present study, we investigated the expression levels of
miR-141 in NSCLC tissues and examined its effects on NSCLC cell
proliferation and tumor growth. We also investigated the involve-
ment of PH domain leucine-rich-repeats protein phosphatase 1
(PHLPP1) and PHLPP2 in miR-141 activity in NSCLC cells and in
clinical samples. The results of this study will provide further
insights into the mechanisms responsible for NSCLC tumorigenesis,
and identify miR-141 as a potential therapeutic target in NSCLC
treatment.
2. Materials and methods
2.1. Clinical specimens and cell lines
Fresh cancer tissues and matched adjacent non-cancerous
tissues were obtained from 12 NSCLC patients at The Fifth People’s
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nitrogen in the operating room and stored at 80 C until extrac-
tion of total RNA. Prior written informed consent and Institutional
Ethics Committee approval were obtained for the use of these
clinical materials for research purposes. The NSCLC cell lines
A549 and H460 were purchased from Cell Banks of Shanghai Insti-
tutes of Biological Sciences (Shanghai, China) and cultured in
DMEM (Invitrogen, Carlsbad, CA, USA) in the presence of 10% fetal
bovine serum, 100 units/ml penicillin and 100 g/ml streptomycin
in a humidiﬁed 5% (v/v) CO2 atmosphere at 37 C in an incubator.
2.2. Quantitative real-time polymerase chain reaction (qRT-PCR)
The expression levels of miR-141 were determined by TaqMan
qRT-PCR according to the TaqMan MicroRNA Assay protoco
l (Applied Biosystems, Foster City, CA, USA) and normalized using
U6 small nuclear RNA. The relative expression level of miR-141 in
each set of paired tumor and non-tumor tissues was measured by
the 2DDCT method. The expression levels of PHLPP1 and PHLPP2
were determined using primers designed according to primer 3.0 on
line and the primer sequences were as follows: PHLPP1-sense:
50-CCTACCTTCTCCAGTGCACT-30;PHLPP1-antisense:50-CCAGCAGTTCC
AAGTTTCCT-30; PHLPP2-sense: 50-GGACGAGAGGAGGTGGAATA-30;




2.3. Plasmids and transfection
The miR-141 mimic (miR-141), miR-141 inhibitor (miR-141-in)
and their respective controls (NC and NC-in) were designed and
synthesized from RiboBio (RiboBio Co. Ltd., Guangzhou, Guang-
dong, China). Transfection was carried out using Lipofectamine
2000 reagent (Invitrogen) according to the manufacturer’s instruc-
tions. Cells were prepared for qRT-PCR and western blotting at 48 h
after transfection. To overexpress PHLPP1 and PHLPP2, the PHLPP1
and PHLPP2 open reading frames were ampliﬁed and cloned into
pcDNA vector (Invitrogen). The empty vector served as a negative
control. Cells were transfected with the vectors using Lipofect-
amine 2000.
2.4. Cell proliferation and cell cycle assay
The cells were seeded onto 96-well plates at a density of
2  103/well in a ﬁnal volume of 100 ll and cultured overnight
in a humidiﬁed 5% (v/v) CO2 atmosphere in a 37 C incubator.
Transfection was carried out when the cells became adherent. After
incubation for 24, 48, 72 and 96 h, 20 ll MTT (Merck Millipore,
Billerica, MA, USA) (5 mg/ml) in phosphate-buffered saline was
added to each well and the cells were incubated at 37 C for a
further 4 h. A total of 150 ll dimethyl sulfoxide was added to the
cells in each well after the supernatants were discarded. The absor-
bance of each well was measured at 490 nm using a microplate
reader. For cell cycle analysis, cells were seeded in 6-well plates
at 2  105/well. At 48 h after transfection, cells were ﬁxed in 70%
ethanol at 4 C overnight and stained with 50 lg/ml propidium
iodide for 30 min. The cells were analyzed using a FACSCaliber ﬂow
cytometry (BD Bioscience, MA, USA).
2.5. Western blotting
Cells in culture were lysed using RIPA buffer (Beyotime, China)
along with a protease inhibitor cocktail (Roche). The lysates were
analyzed using a BCA Protein Assay Kit (Pierce, Rockford, IL,
USA). Proteins were electrophoresed in 10% sodium dodecyl sulfatepolyacrylamide gels and transferred onto nitrocellulose mem-
branes. The membranes were incubated with primary antibodies
against PHLPP1, PHLPP2, AKT, and p-AKT (Abcam, Cambridge,
MA, USA), followed by horseradish peroxidase (HRP)-conjugated
secondary antibodies, and incubated at room temperature for 1 h.
Signals were detected by chemiluminescence reaction with HRP
substrate. GAPDH was used as a loading control.
2.6. Vector construction and luciferase report assay
The human PHLPP1-30UTR and PHLPP2-30UTR target sequences
were ampliﬁed by PCR from human genomic DNA using the
following primers: 50-TGCTGTCTGCATGTTCCTGGCCTC-30 (For-
ward) and 50-ATCTTAGCCAGCAGCTCAGTCAGG-30 (Reverse) for
PHLPP1-30UTR; 50-TGCTGTCTGCATGTTCCTGGCCTC-30 (Forward)
and 50-ATCTTAGCCAGCAGCTCAGTCAGG-30 (Reverse) for PHLPP2-
30UTR. As a negative control, mutations were generated by
mutating the seed regions of the miR-141 binding site using a
QuickChange Site-Directed Mutagenesis kit (Stratagene, Santa
Clara, CA). Each sequence was cloned into the pGL3-luciferase
reporter vector (Promega, Madison, WI, USA) and the construct
was veriﬁed by sequencing. Luciferase reporter assays were
performed as previously described [12]. Brieﬂy, cells were
transfected with luciferase reporter and pRL-TK Renilla plasmid
(Promega) in combination with miR-141 mimics or miR-NC using
the Lipofectamine 2000. After 48 h, cells were lysed and the
proteins were harvested. Luciferase and Renilla activities were
measured using the Dual-GLO Luciferase Assay System (Promega)
according to the manufacturer’s protocol.
2.7. In vivo models and immunohistochemistry
All animal studies were approved by the Animal Care and Use
Committee of Fudan University, China. The stable miR-141-overex-
pression cell line A549-miR-141 was generated by lentivirus
system expressing miR-141-GFP as described previously [13].
A549-miR-141 or A549-NC cells (1  106) were injected into the
right back of nude mice (4 weeks of age, male, BALB/c; n = 5 mice
in each group). The subcutaneous tumors were weighed and the
length and width of the tumors were measured with calipers.
Tumor volume was calculated using the formula: length width2
 0.5. After antigen retrieval in sodium citrate buffer and quench-
ing of endogenous peroxidase activity with 3% H2O2 in methanol,
tissue sections (5 lm thick) were incubated with primary antibod-
ies against Ki-67 (Abcam). The Envision + peroxidase system and
DAB-chromogen were applied (Dako Japan Inc., Tokyo, Japan).
Sections were counterstained with hematoxylin.
2.8. Statistical analysis
The data were expressed as the mean ± standard deviation
(S.D.) based on at least three separate experiments performed in
triplicate. The relationships between miR-141 expression and
PHLPP1 and PHLPP2 mRNA expression levels were analyzed using
Pearson’s correlation analyses. Statistical signiﬁcance was deter-
mined using Student’s t-tests. A value of P < 0.05 was considered
statistically signiﬁcant.3. Results
3.1. miR-141 is up-regulated in NSCLC tissues
We ﬁrst determined the expression patterns of miR-141 by
qRT-PCR analysis in 12 pairs of NSCLC and matched adjacent
non-cancerous lung tissues. As shown in Fig. 1A, the expression
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compared to that in non-cancerous lung tissues, suggesting that
miR-141 might be involved in human NSCLC development.
3.2. miR-141 promotes proliferation of NSCLC cells in vitro
To explore the biological function of miR-141, we transfected
two commonly used NSCLC cell lines, A549 and H460, with chem-
ically synthesized miR-141 mimic (miR-141), miR-141 inhibitor
(miR-141-in) or the corresponding negative controls. The expres-
sion levels of miR-141 were veriﬁed by qRT-PCR (Fig. 1B). MTT
assays showed that overexpression of miR-141 promoted the via-
bility of both cell lines, while inhibition of miR-141 had the oppo-
site effect on cell proliferation, suggesting a growth-promoting role
of miR-141 in NSCLC (Fig. 1C). Furthermore, ﬂow cytometry analy-
sis showed that miR-141 signiﬁcantly increased the percentage of
cells in S phase and decreased the proportion in G0/G1 phase.
In contrast, miR-141 knockdown cells displayed a signiﬁcantFig. 1. miR-141 is up-regulated in NSCLC and promotes NSCLC cell proliferation. (A) R
cancerous lung tissues from 12 patients. (B) Expression levels of miR-141 were tested by
141inhibitor (miR-141-in) or their respective controls. (C) MTT assays of the transfectedreduction in the S-phase population and an increase in the
G0/G1-phase population (Fig. 1D). These results suggest that
miR-141 could promote the proliferation of NSCLC cells by
promoting cell cycle progression.
3.3. miR-141 promotes NSCLC tumor growth in vivo
To clarify the effect of miR-141 on NSCLC cell growth in vivo,
nude mice were subcutaneously inoculated with A549 cells stably
expressing miR-141 by lentivirus infection. Tumor volume was
measured every 3 days, and mice were sacriﬁced 30 days after
tumor cell implantation. As shown in Fig. 2A, tumors in the
A549-miR-141 group grew more rapidly than those in the A549-
NC group. Tumor size and weight were signiﬁcantly greater in
the miR-141 overexpression group compared with the control
group (Figs. 2B and C). Moreover, miR-141 expression was
signiﬁcantly up-regulated in A549-miR-141 xenograft tumor
tissues (Fig. 2D). The proliferative Ki-67 expression indexes inelative expression levels of miR-141 in NSCLC tissues and matched adjacent non-
qRT-PCR in A549 and H460 cells transfected with miR-141 mimic (miR-141), miR-
cell lines. (D) Cell cycle analysis. ⁄P < 0.05.
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NC tumors, as conﬁrmed by immunohistochemical staining (Fig. 2E).
3.4. miR-141 directly targets PHLPP1 and PHLPP2
To identify the potential target genes of miR-141, we used two
publicly available bioinformatic algorithms, TargetScan and miR-
anda in combination. The results identiﬁed PHLPP1 and PHLPP2,
which are phosphatases that directly dephosphorylate AKT, pro-
mote apoptosis and suppress tumor growth [14–16], as theoretical
target genes of miR-141. The predicted binding sites between miR-
141 and PHLPP1 and PHLPP2 30-UTRs are illustrated in Fig. 3A. The
expression levels of PHLPP1 and PHLPP2 were obviously decreased
in A549 and H460 cells transfected with miR-141 mimics, but were
increased after inhibition of miR-141 (Fig. 3B and C). Moreover, the
protein levels of phosphorylated AKT were obviously increased in
both miR-141-overexpressing cell lines as a result of miR-141 tar-
geted reduction of PHLPP1 and PHLPP2 expression levels, but were
decreased after inhibition of miR-141 (Fig. 3B). These results were
consistent with the functions of PHLPP1 and PHLPP2 to dephos-
phorylate AKT directly [14–16]. To further determine if the sup-
pressive effects of miR-141 on PHLPP1 and PHLPP2 were direct
actions, the fragments containing the miR-141 binding sites of
the wild-type and mutant 30-UTRs of PHLPP1 and PHLPP2 were
subcloned into a luciferase reporter vector. As shown in Fig. 3D,
miR-141 suppressed PHLPP1 and PHLPP2 luciferase activities in
A549 and H460 cells, respectively, which could be abrogated by
mutations in the miR-141 binding sites, suggesting that miR-141
directly targets PHLPP1 and PHLPP2.
3.5. Repression of PHLPP1 and PHLPP2 plays crucial roles in miR-141-
induced proliferation of NSCLC cells
To conﬁrm whether the proliferation-promoting role of
miR-141 in NSCLC cells was attributable to decreased expressionFig. 2. Upregulation of miR-141 in NSCLC cells promotes tumor growth in vivo. (A) miR
with LV-NC or LV-miR-141 were subcutaneously injected into nude mice and tumor v
tumors from nude mice. (C) Tumor weight. (D) Levels of miR-141 in xenograft tumor ti
xenografted tumors. ⁄P < 0.05.of PHLPP1 and PHLPP2, we restored the expression of PHLPP1
and PHLPP2 in miR-141-overexpressing A459 and H460 cells by
transfection of PHLPP1 and PHLPP2 without the 30-UTR (Fig. 4A).
MTT assay showed that re-introduction of PHLPP1 or PHLPP2 or
both signiﬁcantly decreased the growth rate of miR-141-over-
expressing A459 and H460 cells (Fig. 4B). In addition, ﬂow
cytometry analysis showed that re-introduction of PHLPP1 or
PHLPP2 or both into miR-141-overexpressing NSCLC cells signiﬁ-
cantly increased the percentage of cells in G0/G1 phase and
decreased the percentage in S phase (Fig. 4C). These results demon-
strate that repression of PHLPP1 and PHLPP2 plays a crucial role in
the miR-141-induced proliferation of NSCLC cells.
3.6. PHLPP1 and PHLPP2 were down-regulated in NSCLC specimens
and inversely correlated with miR-141 levels
We further examined the expression levels of PHLPP1 and
PHLPP2 in clinical NSCLC samples. Analyses of 12 sets of human
NSCLC and matched adjacent non-cancerous lung tissues showed
that PHLPP1 and PHLPP2 expression levels were down-regulated
in a high proportion of clinical samples (10/12) (Fig. 5A). In addi-
tion, correlation analyses revealed that miR-141 levels were nega-
tively correlated with PHLPP1 and PHLPP2 expression levels in
NSCLC tissues (Fig. 5B). These ﬁndings demonstrate that miR-141
negatively regulates PHLPP1 and PHLPP2 in NSCLC in a clinical
situation.
4. Discussion
miRNAs are a large group of genes that negatively regulate the
expression of their target genes in a sequence-speciﬁc manner [6].
Emerging evidence has shown that miRNAs play essential roles in
tumorigenesis [17,18], and the dysregulation of miRNAs has been
identiﬁed in various types of tumors [19]. Moreover, several-141 promoted tumorigenicity in a nude mice xenograft model. A549 cells infected
olumes were measured on the indicated days. (B) Representative graph of excised
ssues were determined by qRT-PCR. (E) H&E and Ki67 staining were carried out on
Fig. 3. miR-141 targets PHLPP1 and PHLPP2 genes. (A) miR-141 binding sites in the PHLPP1 30-UTR and PHLPP2 30-UTR. Mutations in the complementary site for the seed
region of miR-141 in 30-UTR of PHLPP1 and PHLPP2 genes are indicated. (B and C) Western blot and qRT-PCR analyses of PHLPP1 and PHLPP2 expression in A549 and H460
cells transfected with miR-141 mimic or miR-141-in. (D) Wild-type or mutant reporter plasmids were cotransfected with miR-141 or miR-141-in in A549 (left panel) and
H460 (right panel) cells. Luciferase activity determined 48 h after transfection. ⁄P < 0.05.
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and therapy of lung cancer [20,21].
miR-141, a member of the miR-200 family, has been reported to
be associated with various cancers [22]. It is down-regulated and
acts as a potential tumor suppressor in hepatocellular carcinoma
[10], pancreatic ductal adenocarcinoma [23] and renal cell carci-
noma [24]. However, miR-141 has also been shown to exhibit
oncogenic properties in nasopharyngeal carcinoma, suggesting
that it plays dual roles in different cancers. Liu and colleagues pre-
viously demonstrated that the expression levels of miR-141 in
NSCLCs were higher than those in normal tissues [25]; however,
no further results have been reported regarding the expression,
function, and mechanisms of miR-141 in NSCLC. The results of
the present study demonstrated that miR-141 was up-regulated
in human NSCLC. Moreover, miR-141 could accelerate G1/S phase
transition and promote proliferation of NSCLC cells in vitro and
tumor growth in vivo, suggesting an oncogenic role in NSCLC.We further investigated the molecular mechanisms whereby
miR-141 promotes the proliferation of NSCLC cells. Publicly-avail-
able bioinformatic algorithms predicted PHLPP1 and PHLPP2 as
theoretical target genes of miR-141. PHLPP1 and PHLPP2 are antag-
onists of PI3K/AKT signaling and inhibit AKT signaling activity by
directly dephosphorylating AKT, which plays crucial roles in cell
proliferation, survival, differentiation and migration [26–28]. Our
results indicated that PHLPP1 and PHLPP2 expression were
suppressed by miR-141 in NSCLC cells, while inhibition of miR-
141 could rescue the expression of PHLPP1 and PHLPP2. Luciferase
reporter assays revealed that miR-141 could directly target the
30-UTRs of PHLPP1 and PHLPP2 mRNAs. Moreover, re-introduction
of PHLPP1 and PHLPP2 signiﬁcantly abrogated miR-141-induced
proliferation of NSCLC cells. In clinical NSCLC tissues, the expres-
sion levels of PHLPP1 and PHLPP2 were inversely correlated with
miR-141 levels. These results suggest that miRNA-141 promotes
the proliferation of NSCLC cells by negatively regulating the
Fig. 4. Re-introduction of PHLPP1 and/or PHLPP2 abrogated miR-141-induced proliferation of NSCLC cells. miR-141-overexpressing cells were transfected with PHLPP1,
PHLPP2 (without the 30-UTR), or empty vector. (A) Western blotting was used to detect the expression of PHLPP1 and PHLPP2, using GAPDH for normalization. (B) MTT assays
were used to assess cell viability. The optical density values (490 nm) of cells at day 4 were measured. (C) Flow cytometric analysis was used to detect the cell cycle
distribution. ⁄P < 0.05.
Fig. 5. PHLPP1 and PHLPP2 expression levels were inversely correlated with miR-141 levels. (A) Expression levels of PHLPP1 and PHLPP2 in 12 NSCLC specimens were
assessed by qRT-PCR. Data represent mean ± S.D. from three independent experiments. (B) Pearson’s correlation analyses between miR-141 levels and mRNA expression
levels of PHLPP1 and PHLPP2 in 12 human NSCLC tissues. ⁄P < 0.05.
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of these genes.
AKT plays a crucial role in controlling the balance between pro-
liferation and quiescence, as well as cell survival and apoptosis
[14]. The dysregulation of AKT-regulated processes leads to patho-
logical states and drives diseases such as cancer [15,27,29]. Along
with phosphatase and tensin homolog deleted on chromosome
ten (PTEN), a well-known tumor suppressor in the AKT signal path-
way, PHLPP1 and PHLPP2 have been shown to be down-regulated
in many cancers [3,14]. However, the regulatory functions of
PHLPP1 and PHLPP2 in lung cancer remain to be explored. Our
results showed that PHLPP1 and PHLPP2 expression levels were
down-regulated in NSCLC tissues compared with matched adjacent
non-cancerous tissues. Re-introduction of PHLPP1 and PHLPP2 sig-
niﬁcantly antagonized miR-141-induced proliferation of NSCLC
cells, suggesting that PHLPP1 and PHLPP2 function in inhibiting
the proliferation of NSCLC cells. Furthermore, miR-141-induced
down-regulation of PHLPP1 and PHLPP2 signiﬁcantly increased
the level of phosphorylated AKT, conﬁrming that miR-141 acti-
vated AKT signaling, thus modulating NSCLC cell proliferation.
In conclusion, the results of this study suggest that miR-141 is
up-regulated in NSCLC and plays an important role in the prolifer-
ation of NSCLC cells by targeting PHLPP1 and PHLPP2. miR-141
may therefore represent a potential therapeutic target for NSCLC
treatment.
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